Zhang L, McCabe T, Condra JH, Ni YG, Peterson LB, Wang W, et al. An anti-PCSK9 antibody reduces LDL-cholesterol on top of a statin and suppresses hepatocyte SREBP-regulated genes. Int J Biol Sci. 2012;8(3):310–27.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Duff CJ, Scott MJ, Kirby IT, Hutchinson SE, Martin SL, Hooper NM. Antibody-mediated disruption of the interaction between PCSK9 and the low-density lipoprotein receptor. Biochem J. 2009;419(3):577–84.

Article  CAS  PubMed  Google Scholar 

Trinder M, Li X, DeCastro Maria L, Cermakova L, Sadananda S, Jackson Linda M, et al. Risk of premature atherosclerotic disease in patients with monogenic Versus Polygenic Familial Hypercholesterolemia. J Am Coll Cardiol. 2019;74(4):512–22.

Article  PubMed  Google Scholar 

Hedegaard Berit S, Bork Christian S, Kaltoft M, Klausen Ib C, Schmidt Erik B, Kamstrup Pia R, et al. Equivalent Impact of Elevated Lipoprotein(a) and familial hypercholesterolemia in patients with atherosclerotic Cardiovascular Disease. J Am Coll Cardiol. 2022;80(21):1998–2010.

Article  PubMed  Google Scholar 

McCormack T, Dent R, Blagden M. Very low LDL-C levels may safely provide additional clinical cardiovascular benefit: the evidence to date. Int J Clin Pract. 2016;70(11):886–97.

Article  CAS  PubMed  Google Scholar 

Soran H, Dent R, Durrington P. Evidence-based goals in LDL-C reduction. Clin Res Cardiol. 2017;106(4):237–48.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Banach M, Reiner Z, Cicero AFG, Sabouret P, Viigimaa M, Sahebkar A et al. 2022: The year in cardiovascular disease – the year of upfront lipid lowering combination therapy. Archives of Medical Science. 2022;18(6):1429–34.

PubMed  PubMed Central  Google Scholar 

Bahrami A, Bo S, Jamialahmadi T, Sahebkar A. Effects of 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors on ageing: Molecular mechanisms. Ageing Res Rev. 2020;58:101024.

Article  CAS  PubMed  Google Scholar 

Bland AR, Payne FM, Ashton JC, Jamialahmadi T, Sahebkar A. The cardioprotective actions of statins in targeting mitochondrial dysfunction associated with myocardial ischaemia-reperfusion injury. Pharmacol Res. 2022;175:105986.

Article  CAS  PubMed  Google Scholar 

Chruściel P, Sahebkar A, Rembek-Wieliczko M, Serban MC, Ursoniu S, Mikhailidis DP, et al. Impact of statin therapy on plasma adiponectin concentrations: a systematic review and meta-analysis of 43 randomized controlled trial arms. Atherosclerosis. 2016;253:194–208.

Article  PubMed  Google Scholar 

Gorabi AM, Kiaie N, Pirro M, Bianconi V, Jamialahmadi T, Sahebkar A. Effects of statins on the biological features of mesenchymal stem cells and therapeutic implications. Heart Fail Rev. 2021;26(5):1259–72.

Article  PubMed  Google Scholar 

Sahebkar A, Kotani K, Serban C, Ursoniu S, Mikhailidis DP, Jones SR, et al. Statin therapy reduces plasma endothelin-1 concentrations: a meta-analysis of 15 randomized controlled trials. Atherosclerosis. 2015;241(2):433–42.

Article  CAS  PubMed  Google Scholar 

Serban C, Sahebkar A, Ursoniu S, Mikhailidis DP, Rizzo M, Lip GYH et al. A systematic review and meta-analysis of the effect of statins on plasma asymmetric dimethylarginine concentrations. Sci Rep. 2015;9902. https://doi.org/10.1038/srep09902.

Article  Google Scholar 

Sohrevardi SM, Nasab FS, Mirjalili MR, Bagherniya M, Tafti AD, Jarrahzadeh MH, et al. Effect of atorvastatin on delirium status of patients in the intensive care unit: a randomized controlled trial. Archives Med Sci. 2021;17(5):1423.

Article  CAS  Google Scholar 

Vahedian-Azimi A, Mohammadi SM, Banach M, Beni FH, Guest PC, Al-Rasadi K, et al. Improved COVID-19 Outcomes following Statin Therapy: An Updated Systematic Review and Meta-analysis. BioMed Research International. 2021;2021:1901772.

Google Scholar 

Sahebkar A, Chew GT, Watts GF. Recent advances in pharmacotherapy for hypertriglyceridemia. Prog Lipid Res. 2014;56(1):47–66.

Article  CAS  PubMed  Google Scholar 

Mollazadeh H, Tavana E, Fanni G, Bo S, Banach M, Pirro M, et al. Effects of statins on mitochondrial pathways. J Cachexia Sarcopenia Muscle. 2021;12(2):237–51.

Article  PubMed  PubMed Central  Google Scholar 

Chamani S, Liberale L, Mobasheri L, Montecucco F, Al-Rasadi K, Jamialahmadi T et al. The role of statins in the differentiation and function of bone cells. Eur J Clin Invest. 2021;51(7).

Article  CAS  PubMed  Google Scholar 

Bahrami A, Parsamanesh N, Atkin SL, Banach M, Sahebkar A. Effect of statins on toll-like receptors: a new insight to pleiotropic effects. Pharmacol Res. 2018;135:230–8.

Article  CAS  PubMed  Google Scholar 

Ferretti G, Bacchetti T, Sahebkar A. Effect of statin therapy on paraoxonase-1 status: a systematic review and meta-analysis of 25 clinical trials. Prog Lipid Res. 2015;60:50–73.

Article  CAS  PubMed  Google Scholar 

Kandelouei T, Abbasifard M, Imani D, Aslani S, Razi B, Fasihi M, et al. Effect of Statins on Serum level of hs-CRP and CRP in Patients with Cardiovascular Diseases: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Mediators Inflamm. 2022;2022:8732360.

Article  PubMed  PubMed Central  Google Scholar 

Parizadeh SMR, Azarpazhooh MR, Moohebati M, Nematy M, Ghayour-Mobarhan M, Tavallaie S, et al. Simvastatin therapy reduces prooxidant-antioxidant balance: results of a placebo-controlled cross-over trial. Lipids. 2011;46(4):333–40.

Article  CAS  PubMed  Google Scholar 

Kouhpeikar H, Delbari Z, Sathyapalan T, Simental-Mendía LE, Jamialahmadi T, Sahebkar A. The Effect of Statins through Mast Cells in the Pathophysiology of Atherosclerosis: a Review. Curr Atheroscler Rep. 2020;22(5):19.

Article  CAS  PubMed  Google Scholar 

Sahebkar A, Kiaie N, Gorabi AM, Mannarino MR, Bainaconi V, Jamialahmadi T, et al. A comprehensive review on the lipid and pleiotropic effects of pitavastatin. Prog Lipid Res. 2021;84:101127.

Article  CAS  PubMed  Google Scholar 

Laufs U, Banach M, Mancini GBJ, Gaudet D, Bloedon LT, Sterling LR, et al. Efficacy and safety of Bempedoic Acid in patients with hypercholesterolemia and statin intolerance. J Am Heart Association. 2019;8(7):e011662.

Article  Google Scholar 

Bytyçi I, Penson PE, Mikhailidis DP, Wong ND, Hernandez AV, Sahebkar A, et al. Prevalence of statin intolerance: a meta-analysis. Eur Heart J. 2022;43(34):3213–23.

Article  PubMed  PubMed Central  Google Scholar 

Sahebkar A, Watts GF. New LDL-cholesterol lowering therapies: Pharmacology, clinical trials, and relevance to acute coronary syndromes. Clin Ther. 2013;35(8):1082–98.

Article  CAS  PubMed  Google Scholar 

Sahebkar A, Watts GF. New therapies targeting apoB metabolism for high-risk patients with inherited dyslipidaemias: what can the clinician expect? Cardiovasc Drugs Ther. 2013;27(6):559–67.

Article  CAS  PubMed  Google Scholar 

Kosmas CE, Pantou D, Sourlas A, Papakonstantinou EJ, Echavarria Uceta R, Guzman E. New and emerging lipid-modifying drugs to lower LDL cholesterol. Drugs Context. 2021;10:2021-8-3.

Michaeli DT, Michaeli JC, Albers S, Boch T, Michaeli T. Established and emerging lipid-lowering drugs for primary and secondary Cardiovascular Prevention. Am J Cardiovasc Drugs. 2023;23(5):477–95.

Article  PubMed  PubMed Central  Google Scholar 

Pang J, Chan DC, Watts GF. The knowns and unknowns of Contemporary Statin Therapy for Familial Hypercholesterolemia. Curr Atheroscler Rep. 2020;22(11):64.

Article  PubMed  PubMed Central  Google Scholar 

Brandts J, Dharmayat KI, Vallejo-Vaz AJ, Azar Sharabiani MT, Jones R, Kastelein JJP, et al. A meta-analysis of medications directed against PCSK9 in familial hypercholesterolemia. Atherosclerosis. 2021;325:46–56.

Article  CAS  PubMed  Google Scholar 

Hasan MM, Laws M, Jin P, Rahman KM. Factors influencing the choice of monoclonal antibodies for antibody–drug conjugates. Drug Discovery Today. 2022;27(1):354–61.

Article  CAS  PubMed  Google Scholar 

Guo Y, Yan B, Gui Y, Tang Z, Tai S, Zhou S, et al. Physiology and role of PCSK9 in vascular disease: potential impact of localized PCSK9 in vascular wall. J Cell Physiol. 2021;236(4):2333–51.

Article  CAS  PubMed  Google Scholar 

Horton JD, Cohen JC, Hobbs HH. Molecular biology of PCSK9: its role in LDL metabolism. Trends Biochem Sci. 2007;32(2):71–7.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Barale C, Melchionda E, Morotti A, Russo I. PCSK9 Biology and Its Role in Atherothrombosis. Int J Mol Sci. 2021; 22(11):5880.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Tombling BJ, Zhang Y, Huang Y-H, Craik DJ, Wang CK. The emerging landscape of peptide-based inhibitors of PCSK9. Atherosclerosis. 2021;330:52–60.

Article  CAS  PubMed  Google Scholar